Joe Biden diagnosed with aggressive prostate cancer that has spread to bones

Joe Biden diagnosed with aggressive prostate cancer that has spread to his bones, his office confirmed on Sunday.


Pop Culture & Art May 19, 2025
U.S. President Joe Biden stands onstage during Day 1 of the Democratic National Convention (DNC) at the United Center, in Chicago, Illinois, U.S., August 19, 2024. PHOTO:REUTERS

Former U.S. President Joe Biden has been diagnosed with an aggressive form of prostate cancer, according to an official statement released by his personal office on Sunday, May 18, 2025.

The cancer has metastasized to his bones, marking a serious development in the 82-year-old leader’s health.

“Last week, President Joe Biden was seen for a new finding of a prostate nodule after experiencing increasing urinary symptoms,” the statement read. “On Friday, he was diagnosed with prostate cancer, characterized by a Gleason score of 9 (Grade Group 5) with metastasis to the bone.”

The Gleason score is a grading system used to assess the aggressiveness of prostate cancer. A score of 9 falls into the highest risk category, indicating a fast-growing and potentially life-threatening form of the disease.

Despite the severity of the diagnosis, Biden’s office noted that the cancer appears to be hormone-sensitive, which allows for effective treatment options such as hormone therapy. The former president and his family are currently reviewing treatment plans in consultation with his physicians.

This marks one of the most serious health updates concerning Biden since his departure from office. The diagnosis comes amid ongoing public interest in the health of past and present American leaders.

Further updates are expected as Biden’s team continues to evaluate treatment paths and issue public statements. The news has prompted widespread concern and well-wishes from political leaders and supporters across the country.



 

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ